Comparative Pharmacology
Head-to-head clinical analysis: AEROSEB DEX versus FLUONID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AEROSEB DEX versus FLUONID.
AEROSEB-DEX vs FLUONID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
The combination product contains a corticosteroid (dexamethasone) which suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and a topical antibiotic (usually neomycin or polymyxin B) which inhibits bacterial protein synthesis or disrupts bacterial cell membranes.
Fluocinolone acetonide is a corticosteroid that binds to the glucocorticoid receptor, leading to inhibition of phospholipase A2, reduction of prostaglandin and leukotriene synthesis, and suppression of inflammatory mediators.
2 puffs (100 mcg each) intranasally twice daily
0.05% cream or ointment applied topically to affected area once daily. Not to exceed 30 g per week.
None Documented
None Documented
Terminal elimination half-life is 12-15 hours in adults with normal renal function; prolonged to 24-30 hours in severe renal impairment (CrCl <30 mL/min).
3.5 hours; prolonged to 18–24 hours in severe hepatic impairment.
Renal elimination of unchanged drug accounts for 30-40% of the dose; fecal/biliary elimination is 50-60% as metabolites. Less than 10% is excreted unchanged in feces.
Renal 70% as unchanged drug, biliary/fecal 30% as metabolites.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid